Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.

Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.
复制标题

DOI:
10.1111/jmwh.13283
复制
发表时间:
2021-11
期刊:
Journal of midwifery & women's health
影响因子:
--
通讯作者:
Novick AM
Novick AM
中科院分区:
其他
文献类型:
--
作者:
Pettigrew JA;Novick AM

文献摘要

参考文献

相似文献

在美国,近一半的女性报告性功能有问题。许多医疗服务提供者在日常临床接触中不会询问性问题,因为个人不适,缺乏对治疗的熟悉,或者认为他们缺乏足够的时间来解决这个复杂的问题。这对于性欲减退症(HSDD)尤其如此,这是女性中最常见的性问题。HSDD的特征是缺乏性思想,感觉或对性刺激的接受能力,至少存在6个月,导致个人痛苦,并且不是由于其他医疗条件。这是一个最新的概述HSDD的临床医生,讨论其生理,评估,诊断和治疗策略。虽然HSDD的明确生理学仍然未知,但多种激素和神经递质可能参与双重控制模型,以平衡性欲的兴奋和抑制。对于评估和诊断,经过验证的筛选工具进行了讨论,并强调了生物心理社会评估的重要性,并指导如何在临床上实施。最近批准的两种药物用于HSDD,氟班色林和布雷默浪肽,以及标签外治疗。总的来说,HSDD代表了一种常见但可能未被充分认识的疾病,助产士和其他在整个生命周期中照顾女性的医疗保健提供者处于独特的地位。关于性欲减退症的评估和管理的最新概述。
Nearly half of women in the United States report problems with sexual function. Many healthcare providers do not ask about sexual concerns during routine clinical encounters because of personal discomfort, lack of familiarity with treatment, or the belief that they lack adequate time to address this complex issue. This may be especially true for hypoactive sexual desire disorder (HSDD), the most commonly identified sexual problem among women. HSDD is characterized by a deficiency of sexual thoughts, feelings or receptiveness to sexual stimulation that has been present for at least 6 months, causes personal distress, and is not due to another medical condition. This is an up-to-date overview of HSDD for clinicians, discussing its physiology, assessment, diagnosis, and treatment strategies. While a definitive physiology of HSDD is still unknown, multiple hormones and neurotransmitters likely participate in a Dual-Control Model to balance excitation and inhibition of sexual desire. For assessment and diagnosis, validated screening tools are discussed, and the importance of a biopsychosocial assessment is emphasized, with guidance on how this can be implemented in clinical encounters. The two recently approved medications for HSDD, flibanserin and bremelanotide, are reviewed as well as off-label treatments. Overall, HSDD represents a common yet likely underrecognized disorder that midwives and other healthcare providers who care for women across the lifespan are in a unique position to address. An up-to-date overview on the evaluation and management of Hypoactive Sexual Desire Disorder.
DOI: 10.1210/jc.2019-01603
发表时间: 2019-10-01
影响因子: 5.8
作者:
Davis, Susan R.;Baber, Rodney;Wierman, Margaret E.
通讯作者: Wierman, Margaret E.
DOI: 10.3390/pharmacy9020071
发表时间: 2021-03-27
期刊: Pharmacy (Basel, Switzerland)
影响因子: --
作者:
Cieri-Hutcherson NE;Jaenecke A;Bahia A;Lucas D;Oluloro A;Stimmel L;Hutcherson TC
通讯作者: Hutcherson TC
DOI: 10.1016/0378-5122(94)00898-h
发表时间: 1995-04-01
期刊: MATURITAS
影响因子: 4.9
作者:
DAVIS, SR;MCCLOUD, P;BURGER, H
通讯作者: BURGER, H
DOI: 10.1016/j.mayocp.2016.09.018
发表时间: 2017-01-01
影响因子: 8.9
作者:
Goldstein, Irwin;Kim, Noel N.;Worsley, Roisin
通讯作者: Worsley, Roisin
DOI: 10.1080/713847125
发表时间: 2003-01-01
影响因子: 2.5
作者:
Ferguson, DM;Steidle, CP;Crosby, MG
通讯作者: Crosby, MG